The maturation of iron-sulfur (Fe/S) proteins in eukaryotes has been intensively studied in yeast. Hardly anything is known so far about the process in higher eukaryotes, even though the high conservation of the yeast maturation components in all Eukarya suggests similar mechanisms. Here, we developed a cell culture model in which the RNAi technology was used to deplete a potential component of Fe/S protein maturation, frataxin, in human HeLa cells. This protein is lowered in humans with the neuromuscular disorder Friedreich's ataxia (FRDA). Upon frataxin depletion by RNAi, the enzyme activities of the mitochondrial Fe/S proteins aconitase and succinate-dehydrogenase were decreased, while the activities of nonFe/S proteins remained constant. Moreover, Fe/S cluster association with the cytosolic iron regulatory protein 1 was diminished. In contrast, no alterations in cellular iron uptake, iron content, and heme formation were found, and no mitochondrial iron deposits were observed
Introduction
Iron-sulfur clusters (ISC) are crucial cofactors of numerous proteins involved in enzyme catalysis, electron transport and regulation of gene expression. The synthesis of these ancient cofactors in the cell requires a complex set of proteins (1) (2) (3) . In bacteria and yeast mitochondria, homologous ISC assembly machineries consisting of some ten proteins have been shown to be essential for maturation of cellular iron-sulfur (Fe/S) proteins. In yeast, this ISC machinery co-operates with additional mitochondrial components and two recently identified cytosolic proteins for maturation of cytosolic and nuclear Fe/S protein (2) . All these components are well conserved in higher eukaryotes such as mouse and man (e.g., 4), and therefore it seems reasonable to expect similar mechanisms of Fe/S protein maturation in these organisms as those defined in yeast. However, direct functional studies in higher eukaryotes have not been reported due to the lack of an efficient experimental system to investigate the role of specific components in Fe/S protein assembly.
The development of the RNA interference (RNAi) technology to specifically deplete gene products (5, 6 ) and the availability of several assays to measure the activity of Fe/S proteins in both mitochondria and the cytosol now offers the possibility to analyse the requirements for Fe/S protein maturation in human cell culture. In the present study frataxin was chosen as an initial component to be examined, because this protein is deficient in the neurodegenerative disorder Friedreich's ataxia (FRDA) (7, 8) . Frataxin is a highly conserved mitochondrial matrix protein with homologs in prokaryotes and eukaryotes (9) (10) (11) (12) (13) . Its three dimensional structure has been elucidated (14) (15) (16) ) but its precise function is still under debate. Mainly based on studies in yeast, the protein was suggested to be involved in the formation of Fe/S proteins (17) (18) (19) . Alternatively, or in addition, the protein might play a role in the storage of mitochondrial iron as suggested by experiments performed in vitro (20, 21) . Moreover, deletion of frataxin in yeast resulted in heme formation defects which, however, were shown to be an indirect consequence of an impaired ISC biogenesis thereby causing a reversible inhibition of ferrochelatase, the enzyme catalysing the last step of heme biosynthesis (22, 23 ).
Friedreich's ataxia (FRDA) is an autosomal recessive inherited mitochondrial disorder that is caused by frataxin deficiency and is characterised by progressive polyneuropathy and myopathy (24) . Mammalian frataxin is expressed in all cells with highest levels in nervous and muscle tissues, explaining why both tissues are preferentially affected in FRDA (25) . A threshold level of frataxin seems to be essential (8, 25) , since in mice a homozygous gene disruption is lethal during embryogenesis (26) . Humans develop clinical signs of FRDA, when frataxin levels drop by about 60% to 70% of normal.
On the cellular level, hallmarks of frataxin deficiency in humans, mice and yeast are mitochondrial iron accumulation, increased sensitivity to oxidants, depletion of mitochondrial DNA, decreased activities of ISC enzymes, and impaired respiration (24, 27, 28) . These observations are consistent with the idea of a vicious cycle in which reactive oxygen species (ROS) are formed by mitochondrial iron deposits via Fenton chemistry and then may destroy ISCs. In turn, disassembly of Fe/S proteins might increase mitochondrial iron accumulation by a still unknown mechanism (29) . However, the initial reason for this vicious cycle is still under debate. On the one hand, human and yeast frataxin were found to form high molecular mass complexes with iron in vitro, indicating that the protein might be an iron storage protein (20, 21) . Without frataxin, iron precipitation and mitochondrial iron accumulation may lead to the FRDA phenotype. On the other hand, yeast frataxin (Yfh1p) interacts with members of the ISC assembly machinery and enhances the formation of ISC in vivo and in vitro, indicating an important role of frataxin in the maturation of Fe/S proteins (17) (18) (19) 30) . Moreover, depletion of frataxin causes similar phenotypes as the depletion of yeast proteins known to be involved in ISC assembly (1, 23, 29, 31) . Another clue that frataxin may play a direct role in ISC at Pennsylvania State University on February 20, 2013 http://hmg.oxfordjournals.org/ Downloaded from formation comes from mouse models for FRDA (26, 32) . Frataxin knock-out mice die at the embryonic stage without any histological signs of iron accumulation, and conditional mouse mutants with a tissue-specific depletion of frataxin develop neuromyopathies with Fe/S protein defects prior to iron accumulation.
In order to analyse the initial biochemical consequences of frataxin deficiency in a controlled fashion from the onset, we developed a human cell culture model for FRDA using an RNAi approach (33) . We found a decreased activity of both mitochondrial and cytosolic Fe/S proteins accompanying frataxin depletion, but we observed no alterations in heme formation, in cellular iron content or in mitochondrial iron deposition. Thus, we conclude that the primary function of human frataxin is in ISC assembly.
Results

Frataxin is efficiently depleted by RNAi
HeLa cells were transfected either with the hFraRNAi plasmid encoding siRNAs interfering with the frataxin mRNA or with the pSUPER control vector. A scrambled siRNA did not cause any detectable specific effects (not shown). Transfection efficiency was assessed by cotransfection with the EGFP-N3 plasmid encoding a green fluorescent protein and resulted in 80% to 90% EGFP + cells as indicated by flow cytometry on each 4 th day after electroporation ( Fig. 1 ; for further details see Materials and Methods). EGFP-fluorescence was similar for both cells transfected with the hFraRNAi or the pSUPER plasmid ( Fig. 1, insert) . When the series of transfections was aborted and cells were cultivated for another 4 or 8 days after analysis, the EGFP-fluorescence decreased over time (Fig. 1, +4 and +8 bars), until hardly any EGFP + cells were detected.
Depletion of frataxin was investigated by immunofluorescence microscopy and immunoblot analysis (Fig. 2) . Already 4 days after the first transfection, HeLa cells co-transfected with the hFraRNAi plasmid displayed considerably decreased levels of frataxin ( Fig. 2A) . Immunoblot analysis revealed a frataxin content of about 40% of the control cells (Fig. 2B, lanes 1 and 2) .
After re-transfection frataxin levels dropped below 20% of the control cells (Fig. 2B, lanes 3 to 10), and the protein was hardly detectable by immunofluorescence ( Fig. 2A) . When the transfection series was aborted, the frataxin content increased and was restored to almost normal levels (Fig. 2B, lanes 11 to 14) . The strong but reversible depletion of frataxin allowed us to study the phenotypical effects associated with frataxin deficiency.
Frataxin deficiency results in growth defects
Depletion of frataxin by RNAi reduced HeLa cell growth in comparison to the pSUPERtransfected control cells (Fig. 3A) . Frataxin-deficient cells did not become confluent as fast as the control cells and their protein content as a measure of cell growth was reduced. Growth retardation appeared after the second transfection, and after four to five transfections the growth rate of the frataxin-depleted cells was less than 50% of the control cells (Fig. 3A, inset). Reduced cell density and protein content were not due to increased cell death because there were no visible signs of apoptosis (not shown). Cell shape and morphology were similar to the pSUPER-transfected control cells. Moreover, staining of frataxin-deficient HeLa cells with the fluorescent dye R6G did not reveal a decreased mitochondrial membrane potential as an indicator for reduced viability (Fig. 3B ). When the transfection series was aborted and the frataxin-depleted cells were further cultured, their growth rate increased, again indicating the reversibility of the RNAi effect (Fig. 3A , time points +4 and +8).
Frataxin deficiency reduces the activities of mitochondrial Fe/S proteins
The importance of frataxin for the function of mitochondrial Fe/S proteins was assessed by measuring the activities of the ISC containing enzymes aconitase and succinate dehydrogenase (SDH). Aconitase and SDH activity of pSUPER-transfected control cells were about 25 and 60 mU/mg protein, respectively (Fig. 4) . In frataxin-deficient cells, aconitase and SDH activity decreased with the time course of frataxin depletion. After four transfections, enzyme activities were up to 40% and 60% lower than in the control cells, respectively. In contrast, the activities of malate dehydrogenase and citrate synthase, two enzymes lacking ISCs, did not differ between frataxin-deficient and control-transfected cells and amounted to 2250 and 225 mU/mg protein, respectively (Fig. 4 ). When the transfection series was aborted, and frataxin was replenished, aconitase and SDH activities were restored to almost normal levels. Thus, frataxin plays an important and specific role in the maintenance of mitochondrial Fe/S protein activities. Our results did not allow us to test whether frataxin plays an additional, iron delivery function in the maintenance of aconitase activity as suggested recently (34) .
Frataxin deficiency increases the RNA binding capabilities of cytosolic IRP1
Nothing is known so far about the maturation of cytosolic Fe/S proteins in human cells and 
No alterations in cellular and mitochondrial iron content upon frataxin depletion
Depletion of the yeast frataxin homologue Yfh1p leads to an increased cellular iron uptake and cellular iron content (9, 10, 37) , and a hallmark of frataxin deficiency in yeast, mouse and man is the accumulation of iron within mitochondria resulting in the formation of iron precipitates (27) . In the present study, cellular iron content of frataxin-deficient and of pSUPER-transfected control cells was analysed by a spectrophotometric assay and was found to be similar, ranging between 1.5 and 2.0 nmol / mg protein (Fig. 6A) . These findings fit to recent observations that IRP1 deletion in mice did not elicit severe effects on the cellular iron status (38) We further asked whether iron deposits were detectable in mitochondria of frataxin-depleted HeLa cells, but no iron precipitates were found by transmission electron microscopy combined with electron dispersion X-ray (EDX) spectroscopy (not shown). The iron status of HeLa cells was not affected within the first three weeks of frataxin deficiency.
In summary, the change in Fe/S protein activities was not due to alterations in the intracellular iron supply, but appeared to be a primary consequence of the depletion of frataxin.
Frataxin deficiency does not affect 55 Fe incorporation into heme
As a final question we asked whether frataxin might play a role in heme formation. Since human ferrochelatase contains a C-terminal Fe/S cluster that is necessary for enzymatic function (39) , an influence of the frataxin depletion on heme biosynthesis might be expected.
The HeLa cell culture model offered the opportunity to examine the heme formation in human cells from the onset of frataxin depletion. Cells were incubated for 18 h with non-transferrinbound 55 Fe chelated by nitrilotriacetic acid (NTA), leading to a comparable 55 Fe uptake in hFraRNAi transfected and control cells (Fig. 6B ). This result supported the findings from above that the iron content of frataxin-deficient HeLa cells was not considerably altered.
Similar to the 55 Fe uptake, incorporation of 55 Fe into heme was not changed during the first days and weeks of frataxin deficiency (Fig. 6C) . Thus, in human cells frataxin depletion does not lead to an immediate defect in heme formation. As in yeast cells, human ferrochelatase might be in large excess so that its partial functional inactivation might not result in immediate consequences for the efficiency of heme synthesis (40) .
Discussion
A deficiency of the mitochondrial protein frataxin is the molecular basis of Friedreich's ataxia, one of the most prevalent inherited ataxias. The mechanisms leading to the phenotypical consequences, such as mitochondrial iron accumulation and Fe/S protein deficiency, are still objects of intense investigation (27) . The present study introduces a human cell culture model for FRDA that provides insights into the molecular consequences of frataxin depletion. Additionally, our experimental set-up provides a general system to study 
Materials and methods
Vector design
Frataxin was depleted in human HeLa cells by RNAi using a pSUPER vector-based (Fig. 1) . EGFPfluorescence was up to 500 times stronger than the autofluorescence, indicating a simultaneous strong expression of the frataxin mRNA-specific siRNAs (Fig. 1, inset) . Retransfection prolonged plasmid expression and slightly increased the overall transfection efficiency. After abortion of the transfection series, fade out of EGFP fluorescence strongly depended on the amount of DNA used for the previous transfections, explaining the large variability in the time course of fluorescence decline (Fig. 1, +4 and +8 bars).
Cell viability was determined by assessing the mitochondrial membrane potential (∆Ψ) (46) using the red fluorescent dye rhodamine 6G (R6G) at a final concentration of 275 nM. R6G is selectively accumulated by mitochondria in a ∆Ψ-dependent manner (47) , allowing the evaluation of cell death-associated loss of ∆Ψ by flow cytometry.
Immunostaining
Human frataxin was labelled by a polyclonal rabbit antibody raised against recombinant human frataxin produced in E. coli. Transfected HeLa cells were grown on cover slips and frataxin was detected by indirect immunofluorescence using the affinity-purified rabbit antifrataxin serum and a TRITC-labelled goat anti-rabbit secondary antibody (Dianova). For SDS-PAGE and subsequent electroblotting, 30 µg to 50 µg HeLa cell protein were applied.
Frataxin was immunostained by the rabbit anti-frataxin serum and its amount was quantified relative to cellular α-tubulin detected by a mouse anti-alpha-tubulin monoclonal antibody (DM1α). Visualisation of antigens was performed by peroxidase-conjugated secondary antibodies in combination with a chemiluminescence assay.
Enzyme assays
Enzyme assays were performed with whole HeLa cells that had been shock-frozen in liquid nitrogen and stored at -80° C. Aconitase activity was determined by a coupled aconitaseisocitrate dehydrogenase assay (48) . Succinate dehydrogenase activity was assessed by the DCIP assay in combination with decyl ubiquinone (49) . Malate dehydrogenase and citrate synthase activity were analysed as described (50, 51) .
Iron-responsive element binding of iron regulatory proteins (IRP)
RNA binding capabilities of IRPs (36) was determined by RNA electrophoretic mobility shift assay (REMSA) as described (52, 53) . In principle, [α- were pre-treated with 2% beta-mercaptoethanol in order to disassemble the ISC especially from IRP1 and to achieve maximal IRE-binding. 55 Fe into HeLa cells and incorporation into heme was determined under conditions described previously for yeast cells (55, 56) . Analysis of total 55 Fe content of cell lysates as a measure of iron uptake and incorporation into heme determined by butyl acetate extraction required data normalisation, since both values reciprocally depended on HeLa cell culture density. Results were normalised by plotting the values for 55 Fe uptake and incorporation into heme against the corresponding cell density. For the control cells a linear regression was calculated, and used for correction of the measurements for both uptake of 55 Fe and incorporation into heme by frataxin-depleted HeLa cells. Cellular iron concentration was spectrophotometrically analysed essentially according to (57) , using the dye Nitro-PAPS as an iron chelator (58) at a final concentration of 130 µM.
Uptake, incorporation into heme and cellular concentration of iron
Electron microscopy
For electron microscopy cells were fixed, scraped off with a rubber policeman, dehydrated 
